Lorenzini, Theo http://orcid.org/0000-0003-3377-032X
Cadilha, Bruno L. http://orcid.org/0000-0001-7045-3898
Obeck, Hannah
Benmebarek, Mohamed-Reda
Märkl, Florian http://orcid.org/0000-0003-4285-0380
Michaelides, Stefanos
Strzalkowski, Thaddäus
Briukhovetska, Daria
Müller, Philipp Jie
Nandi, Sayantan
Winter, Pia
Majed, Lina
Grünmeier, Ruth http://orcid.org/0000-0002-9044-3600
Seifert, Matthias http://orcid.org/0000-0002-6581-6196
Rausch, Svenja
Feuchtinger, Tobias http://orcid.org/0000-0002-8517-9681
Endres, Stefan
Kobold, Sebastian http://orcid.org/0000-0002-5612-4673
Article History
Received: 29 July 2022
Revised: 25 May 2023
Accepted: 19 June 2023
First Online: 4 July 2023
Competing interests
: Parts of this work have been performed for the doctoral thesis of TL. SE and SK are inventors of a patent application on one of the constructs presented herein. SE and SK have received research support from TCR2 Inc, Plectonic GmBH, Tabby Therapeutics, and Arcus Biosciences for work related to the present manuscript. SK has received honoraria from GSK, BMS, Novartis, Miltenyi Biotherapeutics, and TCR2 Inc. SE and SK have obtained licensing fees from TCR2 Inc and Carina Biotech. The authors declare that no other competing financial interests or conflicts of interest exist.
: Primary human T cells were isolated after written informed consent in accordance with the Declaration of Helsinki and approval by the Institutional Review Board of the Ludwig-Maximilians-Universität (Munich, Germany). All animal studies were approved by the local regulatory office on animal experimentation (Regierung von Oberbayern, Munich, Germany).